Luteinizing hormone and cortisol responses to naloxone in normal weight women with bulimia.
The present study was undertaken in order to establish whether alterations in the endogenous opioid control of luteinizing hormone (LH) and ACTH/cortisol secretion occur in bulimic women with normal body weight and normal menstrual cycles. For this purpose, the capability of the opioid antagonist naloxone (4 mg injected as an intravenous bolus at time 0, plus 10 mg infused over 2 hr) to increase the circulating levels of LH and cortisol was tested in nine bulimic women and in nine age- and weight-matched normal controls. All women were tested on the 22nd day of a normal menstrual cycle. Two days later, a control test with normal saline (NaCl 0.9%) instead of naloxone was performed. The basal levels of LH and cortisol were similar in the bulimic and normal subjects and were not modified by the administration of normal saline. In contrast, the administration of naloxone significantly increased plasma LH and cortisol levels in all subjects, with peak LH responses at 30 min and peak cortisol responses at 60 min. The naloxone-induced LH and cortisol increases were significantly higher in the bulimic women than in the normal controls. These data indicate the presence of an increased opioid inhibitory tone in the control of LH and ACTH/cortisol secretion in normal weight bulimic women with normal menstrual cycles.
Coiro
V
V
Institute of Internal Medicine, University of Parma, Italy.
d'Amato
L
L
Marchesi
C
C
Capretti
L
L
Volpi
R
R
Roberti
G
G
Cerri
L
L
Chiodera
P
P
D000328:Adult; D002032:Bulimia / Q000097:blood*; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D007986:Luteinizing Hormone / Q000097:blood*; D009270:Naloxone / Q000494:pharmacology*
D009270:Naloxone; D004958:Estradiol; D007986:Luteinizing Hormone; D006854:Hydrocortisone